These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22459734)

  • 21. [Multidrug-resistant tuberculosis].
    Mori T
    Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):192-4. PubMed ID: 10088371
    [No Abstract]   [Full Text] [Related]  

  • 22. Acquired drug resistance during inadequate therapy in a young child with tuberculosis.
    Garcia-Prats AJ; Willemse M; Seifart HI; Jordaan AM; Werely CJ; Donald PR; Schaaf HS
    Pediatr Infect Dis J; 2014 Aug; 33(8):883-5. PubMed ID: 25222312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The analysis of clinical data about the treatment of linezolid against tuberculosis].
    Nie WJ; Chu NH
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):601-3. PubMed ID: 24252739
    [No Abstract]   [Full Text] [Related]  

  • 24. M tuberculosis drug resistance in AIDS.
    Durrheim DN; Levin J; Weyer K
    Lancet; 1997 Jan; 349(9044):61; author reply 61-2. PubMed ID: 8988144
    [No Abstract]   [Full Text] [Related]  

  • 25. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
    Wasserman S; Meintjes G; Maartens G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DOTS in Haiti.
    Ollé-Goig JE
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):282-3. PubMed ID: 10751080
    [No Abstract]   [Full Text] [Related]  

  • 27. Programmatic management of multidrug-resistant tuberculosis--15 years later.
    Nardell EA
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1280. PubMed ID: 22283883
    [No Abstract]   [Full Text] [Related]  

  • 28. Optimizing the clinical pharmacology of tuberculosis medications.
    Egelund EF; Alsultan A; Peloquin CA
    Clin Pharmacol Ther; 2015 Oct; 98(4):387-93. PubMed ID: 26138226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen.
    Achar J; Berry C; Herboczek K; Parpieva N; Tillyashaykhov MN; Tigay ZN; Khamraev A; Velivela K; Seddon JA; du Cros P
    Emerg Infect Dis; 2015 Nov; 21(11):2105-6. PubMed ID: 26488556
    [No Abstract]   [Full Text] [Related]  

  • 30. Quantifying the impact of drug combination regimens on TB treatment efficacy and multidrug resistance probability.
    Lin YJ; Liao CM
    J Antimicrob Chemother; 2015 Dec; 70(12):3273-82. PubMed ID: 26311836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistant tuberculosis.
    Böttger EC
    Lancet; 2001 Apr; 357(9264):1288-9. PubMed ID: 11421208
    [No Abstract]   [Full Text] [Related]  

  • 32. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.
    Cox HS; Sibilia K; Feuerriegel S; Kalon S; Polonsky J; Khamraev AK; Rüsch-Gerdes S; Mills C; Niemann S
    N Engl J Med; 2008 Nov; 359(22):2398-400. PubMed ID: 19038891
    [No Abstract]   [Full Text] [Related]  

  • 33. Facing multi-drug resistant tuberculosis.
    Sotgiu G; Migliori GB
    Pulm Pharmacol Ther; 2015 Jun; 32():144-8. PubMed ID: 24792579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidrug resistant tuberculosis: a continuing crisis.
    Burki T
    Lancet Infect Dis; 2016 Dec; 16(12):1337-1338. PubMed ID: 27998601
    [No Abstract]   [Full Text] [Related]  

  • 35. [Multidrug-resistant tuberculosis: current epidemiology, therapeutic regimens, new drugs].
    Gómez-Ayerbe C; Vivancos MJ; Moreno S
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():35-8. PubMed ID: 27608311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Increasing transmission of tuberculosis in the world. Multiresistant strains are the greatest threat].
    Tärnvik A
    Lakartidningen; 2000 Nov; 97(48):5590-2. PubMed ID: 11187373
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug-resistant tuberculosis: reality and potential threat.
    Lalloo UG
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):255-8. PubMed ID: 20132610
    [No Abstract]   [Full Text] [Related]  

  • 38. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.
    Rao SP; Lakshminarayana SB; Kondreddi RR; Herve M; Camacho LR; Bifani P; Kalapala SK; Jiricek J; Ma NL; Tan BH; Ng SH; Nanjundappa M; Ravindran S; Seah PG; Thayalan P; Lim SH; Lee BH; Goh A; Barnes WS; Chen Z; Gagaring K; Chatterjee AK; Pethe K; Kuhen K; Walker J; Feng G; Babu S; Zhang L; Blasco F; Beer D; Weaver M; Dartois V; Glynne R; Dick T; Smith PW; Diagana TT; Manjunatha UH
    Sci Transl Med; 2013 Dec; 5(214):214ra168. PubMed ID: 24307692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The monitoring of the drug resistance of the causative agent of tuberculosis in Russia in 1979-1998].
    Dorozhkova IR; Popov SA; Medvedeva IM
    Probl Tuberk; 2000; (5):19-22. PubMed ID: 11077846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan.
    Chien JY; Lai CC; Tan CK; Yu CJ; Hsueh PR
    Clin Infect Dis; 2013 Apr; 56(7):1054-5. PubMed ID: 23175554
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.